See more : Aplicaciones y Tratamiento de Sistemas, S.A. (ATSI.MC) Income Statement Analysis – Financial Results
Complete financial analysis of Rain Therapeutics Inc. (RAIN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Rain Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aries Agro Limited (ARIES.BO) Income Statement Analysis – Financial Results
- SBS Media Holdings Co., Ltd. (101060.KS) Income Statement Analysis – Financial Results
- Strax AB (publ) (STRAX.ST) Income Statement Analysis – Financial Results
- Apollo Pipes Limited (APOLLOPIPE.NS) Income Statement Analysis – Financial Results
- True North Gems Inc. (TNGMF) Income Statement Analysis – Financial Results
Rain Therapeutics Inc. (RAIN)
About Rain Therapeutics Inc.
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 61.40M | 40.77M | 15.37M | 7.29M |
| General & Administrative | 15.74M | 10.74M | 3.59M | 3.54M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.74M | 10.74M | 3.59M | 3.54M |
| Other Expenses | 0.00 | 1.00K | -2.02M | -251.00K |
| Operating Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Cost & Expenses | 77.14M | 51.51M | 18.96M | 10.83M |
| Interest Income | 1.42M | 119.00K | 32.00K | 209.00K |
| Interest Expense | 0.00 | 0.00 | 135.00K | 32.00K |
| Depreciation & Amortization | 80.00K | 120.00K | -1.94M | -14.00K |
| EBITDA | -77.06M | -51.51M | -18.91M | -10.84M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -77.14M | -51.51M | -18.96M | -10.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.42M | 120.00K | -2.13M | -74.00K |
| Income Before Tax | -75.72M | -51.39M | -21.08M | -10.90M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 3.00K | 2.00K | -1.89M | -219.00K |
| Net Income | -75.72M | -51.39M | -19.20M | -10.68M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.71 | -2.65 | -1.80 | -1.00 |
| EPS Diluted | -2.71 | -2.65 | -1.80 | -1.00 |
| Weighted Avg Shares Out | 27.99M | 19.41M | 10.66M | 10.66M |
| Weighted Avg Shares Out (Dil) | 27.99M | 19.41M | 10.66M | 10.66M |
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Rain Oncology Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - RAIN
NEW YORK , Aug. 11, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20, 2021 and May 19, 2023, both dates inclusive (the...
RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit
BENSALEM, Pa. , Aug. 11, 2023 /PRNewswire/ -- Law Offices of Howard G.
RAIN SHAREHOLDER ALERT: Jakubowitz Law Reminds Rain Shareholders of a Lead Plaintiff Deadline of September 12, 2023
NEW YORK , Aug. 11, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Rain Oncology Inc. (NASDAQ: RAIN). To receive updates on the lawsuit, fill out the form:...
Rain Oncology Inc. (RAIN) Q2 2023 Earnings Call Transcript
Rain Oncology Inc. (NASDAQ:RAIN ) Q2 2023 Earnings Call Transcript August 10, 2023 5:00 PM ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Nelson Cabatuan - Acting SVP, Finance Robert Doebele - CSO Conference Call...
Rain Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
– Evaluating a number of opportunities to diversify pipeline in precision oncology – – Submitted data abstracts for milademetan in both MANTRA and MANTRA-2 clinical studies; anticipated presentations at medical conferences in 4Q23 – – Quarter-end cash position of $86.3...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rain Oncology Inc. - RAIN
NEW YORK , Aug. 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN). Such investors are advised to contact Robert S.
RAIN LAWSUIT ALERT: Levi & Korsinsky Notifies Rain Oncology Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Aug. 10, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Rain Oncology Inc. with Losses of $750,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 8, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Rain Oncology Inc. ("Rain" or "the Company") (NASDAQ:RAIN) for violations of 10(b)...
RAIN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 12, 2023 in the Class Action Filed on Behalf of Rain Oncology Inc. Shareholders
NEW YORK , Aug. 8, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Rain Oncology Inc. (NASDAQ: RAIN) alleging that the Company violated federal securities laws. Class...
RAIN Investors Have Opportunity to Lead Rain Oncology Inc. Securities Fraud Lawsuit
LOS ANGELES , Aug. 7, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN).
Source: https://incomestatements.info
Category: Stock Reports